Related Experiment Videos
Antiplatelet therapy for atherosclerotic disorders
F Numano1, Y Kishi, T Ashikaga
1Tokyo Medical and Dental University, Department of Internal Medicine, Japan.
Insights
Low-dose aspirin therapy prevents atherosclerosis by reducing platelet activation and increasing beneficial plasma compounds. This approach offers therapeutic benefits beyond preventing blood clots.
Area of Science:
- Cardiovascular Science
- Hematology
- Pharmacology
Background:
- Platelets play a critical role in atherosclerosis development through vascular injury.
- Activated platelets can directly damage vascular endothelial cells, reducing cyclic AMP (cAMP) levels.
- Antiplatelet therapy is crucial for preventing thrombotic events, vascular injury, and atherosclerosis.
Purpose of the Study:
- To investigate the therapeutic effects of low-dose aspirin on platelet activity and atherosclerosis prevention.
- To evaluate the impact of aspirin on plasma levels of key signaling molecules.
Main Methods:
- In vivo and in vitro studies were conducted to assess platelet-endothelial cell interactions.
- A clinical study monitored patients treated with low-dose aspirin (80 mg) for over 3 years.
- Plasma levels of thromboxane A2, cAMP, and 6-keto PGF1 alpha were measured.
Main Results:
- Low-dose aspirin (80 mg) induced clinical hypoaggregativeness of platelets.
- Aspirin treatment led to decreased plasma levels of thromboxane A2.
- Long-term aspirin therapy increased plasma levels of cAMP and 6-keto PGF1 alpha.
Conclusions:
- Low-dose aspirin therapy demonstrates favorable effects in preventing atherosclerosis.
- Aspirin's benefits are linked to reduced platelet aggregation and modulation of key plasma compounds.
- This therapy offers a dual benefit of preventing thrombosis and vascular injury.
Abstract:
Recent studies have revealed the important roles of platelets in atherogenesis via vascular injury. Our in vivo and in vitro studies clearly demonstrate that activated platelets directly inflict injury to vascular endothelial cells, which is associated with a decrease in intracellular cyclic AMP levels in vascular tissues. Antiplatelet therapy is clinically important not only for the prevention of thrombotic episodes but also for the prevention of vascular injury and atherosclerosis. A small dose of aspirin (80 mg) induces clinically hypoaggregativeness of platelets with concomitantly decreased levels of thromboxane A2 in plasma. Our clinical study involving more than 3 years of treatment with small doses of aspirin demonstrated favorable therapeutic effects characterized by hypoaggregation of platelets and increased levels of cAMP and 6-keto PGF1 alpha in plasma which will aid in the prevention of atherosclerosis.